Orphai Therapeutics Sale to Quince Therapeutics
Cooley advised Orphai Therapeutics, a clinical-stage biotechnology company, on its sale to Quince Therapeutics, a biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. The acquisition brings Orphai’s lead program LAM-001, an inhaled formulation of rapamycin (mTOR inhibitor), to treat rare pulmonary diseases, into Quince’s pipeline.
The transaction was announced publicly in the following press release, which can be viewed here.
The Cooley corporate and M&A team advising Orphai was led by Brittany Wightman, Madison Jones, Rita Sobral, Rama Padmanabhan and Ariel Rom and included associates Kyle Hess, Dillon Holdsworth, Susan Choy, John DelMastro and Mac Taggart.
Partners Adriane Andrade and Nyron Persaud and associates Mark Cornillez-Ty and Breanna Qin provided compensation and benefits advice. Partner Charity Williams and associates John Forrest, Joe Perry and Noah Goldman provided advice on intellectual property matters. Partner Jeffrey Tolin and associate Hardy Zhou advised on tax matters. Special counsel Andrew Epstein and associate Christopher Suhler advised on cyber data privacy matters. Partner Ross Eberly and associates Jacob Lahana and Alyssa Broer provided advice on labor and employment matters.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.